The EC has granted approval for a fixed-duration regimen of AstraZeneca's Calquence (acalabrutinib) plus venetoclax.

AstraZeneca (AZ) has announced that its fixed-duration Calquence (acalabrutinib)-based regimens have been approved by the ...

AstraZeneca (LSE: AZN) has received European approval for a fixed-duration regimen of Calquence (acalabrutinib) in ...

Uniting over 600 industry experts this September 22-25, the 15 th World Clinical Biomarkers & Companion Diagnostics (CDx) ...

"Calquence plus venetoclax is the first and only all-oral combination treatment option with a second-generation BTK inhibitor ...

Drugmaker AstraZeneca said on Friday that it had received approval from the European Commission for fixed-duration regimens ...

OPEN The FTSE 100 was expected to open 6.2 points lower on Friday after closing 0.11% higher in the previous session at 8,811.04.

A fixed-duration regimen of AstraZeneca's Calquence (acalabrutinib) in combination with venetoclax, with or without ...

AstraZeneca continues to impress me with the strong performances of its oncology, cardiovascular, and rare disease franchises. See why AZN stock is a Buy.

AstraZeneca AZN stock has declined 6.4% in the past three months. Although AstraZeneca faces its share of challenges, a significant portion of this price decline is attributed to broader market ...